Can a Follow-Up drug keep bones strong after initial osteoporosis therapy?
NCT ID NCT06164795
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study looks at postmenopausal women with severe osteoporosis who have finished a course of either romosozumab or teriparatide. Researchers want to see which follow-up drug—zoledronate, denosumab, teriparatide, romosozumab, or abaloparatide—best maintains or improves bone density. The goal is to find the most effective sequential treatment to reduce fracture risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zoledronate, denosumab, teriparatide, romosozumab, or abaloparatide
- What this could lead to
- If successful, this study could identify the most effective bone-strengthening drug to use after initial treatment, helping prevent fractures in women with severe osteoporosis.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be influenced by patient selection. Differences in bone density may not translate to fewer fractures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS, POSTMENOPAUSAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
, KAT General Hospital
RECRUITINGAthens, 14561, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
251 Airforce & VA General Hospital
RECRUITINGAthens, 11525, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
424 General Military Hospital
RECRUITINGThessaloniki, 56429, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Campus Bio-Medico University
RECRUITINGRoma, 00128, Italy
Contact
Contact Email: •••••@•••••
Contact
Contact
-
Department of Medicine, Surgery and Neurosciences, University of Siena
RECRUITINGSiena, 53100, Italy
Contact
Contact
Contact Email: •••••@•••••
-
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens
RECRUITINGAthens, 11527, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
Contact
-
University-Hospital S. Maria della Misericordia
RECRUITINGUdine, Italy
Contact
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bone drugs may double as liver fat fighters — a trial puts them to the test
- Can a single infusion lock in bone gains after osteoporosis treatment?
- Could common statins be a surprise weapon against brittle bones?
- Could adding a second drug boost bone strength in osteoporosis?
- New study compares powerful Bone-Building drug combos for osteoporosis
- Gut health may boost bone density: probiotic study shows promise